Emily Stephenson, APRN
Psychiatric/Mental Health · Richmond, INNPI 1215677943
Payments from drug & device makers
Across 196 payments — averaging $15.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$968
- Vanda Pharmaceuticals Inc.$276
- Johnson & Johnson$238
- Axsome Therapeutics, Inc.$208
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$203
- Teva Pharmaceuticals USA, Inc.$189
- plus $1K from 13 others
What the payments were for
- Food & beverage$3,07999%
- Education$421%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 84 | $968 |
| Vanda Pharmaceuticals Inc. | 20 | $276 |
| Johnson & Johnson | 7 | $238 |
| Axsome Therapeutics, Inc. | 12 | $208 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $203 |
| Teva Pharmaceuticals USA, Inc. | 10 | $189 |
| Alkermes, Inc. | 9 | $188 |
| Otsuka America Pharmaceutical, Inc. | 10 | $188 |
| Neurocrine Biosciences, Inc. | 7 | $136 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $122 |
| Lundbeck LLC | 7 | $121 |
| Indivior Inc. | 3 | $66 |
| E.r. Squibb & Sons, L.L.C. | 3 | $49 |
| Collegium Pharmaceutical, Inc. | 2 | $37 |
| Tris Pharma Inc | 2 | $34 |
| Novo Nordisk | 2 | $32 |
| Corium, LLC | 2 | $31 |
| Neos Therapeutics, LP | 1 | $19 |
| Luye Pharma (USA) Ltd. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$114
How this compares
$3,121 in reported general payments places this provider in the 80th percentile of 729 psychiatric/mental health providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 11 | $52,829 |
| VraylarCariprazine Hcl | 32 | $45,360 |
| FetzimaLevomilnacipran Hcl | 26 | $18,847 |
| TrintellixVortioxetine Hydrobromide | 20 | $18,359 |
| RexultiBrexpiprazole | 11 | $15,798 |
| Aripiprazole | 116 | $9,708 |
| Paliperidone ErPaliperidone | 28 | $8,608 |
| Lurasidone Hcl | 24 | $7,121 |
| Bupropion XlBupropion Hcl | 78 | $3,931 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 49 | $3,464 |
| Buspirone Hcl | 101 | $2,685 |
| Duloxetine Hcl | 112 | $2,445 |
| Vilazodone Hcl | 16 | $2,420 |
| Hydroxyzine Hcl | 70 | $2,392 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 26 | $1,928 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Fetzima | $968 | $64,20758 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $189 | $52,82911 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $122 | $18,35920 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $188 | $15,79811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 729 psychiatric/mental health providers in Indiana.
Other psychiatric/mental health in Richmond
- Courtney FullmerRichmond$6K
- Brooke KempfTerre Haute$1.1M
- Gerald LewisMerrillville$336K
- Lauren LutzColumbus$320K
- Sonya RuedlingerIndianapolis$134K
- Trina GreenwaldMarion$107K
- Paul DuncanJeffersonville$46K
- Morgan StamperConnersville$42K
- Jennifer JimenezUnion Mills$37K
- Savannah MullinsClarksville$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.